Eton Pharmaceuticals, Inc. ETON
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2018-11-09
Eton Pharmaceuticals, Inc. statistics & valuation
Market cap$977.9M
P / S12.2×
P / B37.4×
P / FCF96.0×
Net margin-5.8%
Return on equity-17.6%
FCF margin12.7%
Net cash$4.2M
Net debt / EBITDA-1.3×
Enterprise value USD$973.7M
Earnings yield EBIT/EV-0.1%
Return on capital-1.6%
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 53.5% | 60.0% | 66.6% | 67.4% | 87.1% | -1017.9% | 52.8% | — |
| Operating margin | -1.1% | -6.7% | -3.8% | -38.9% | -6.8% | -69515.4% | -1939.6% | — |
| Net margin | -5.8% | -9.8% | -3.0% | -42.4% | -9.0% | -71717.9% | -1910.3% | — |
| FCF margin | 12.7% | 2.4% | 21.5% | 22.5% | -21.7% | -57425.6% | -1994.0% | — |
| Return on assets | -5.0% | -5.0% | -2.9% | -36.0% | -7.1% | -106.3% | -107.3% | -45.0% |
| Return on equity | -17.6% | -15.7% | -6.0% | -69.0% | -11.1% | -158.7% | -173.6% | -48.4% |
| Debt / equity | 0.83× | 1.22× | 0.00× | 0.41× | 0.30× | 0.37× | 0.43× | — |
| Current ratio | 1.57 | 2.06 | 1.65 | 3.10 | 5.18 | 6.51 | 7.65 | 13.59 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.